Short answer
BALCHEM CORP (BCPC) filed its Q3 2026 10-Q quarterly report on Oct 23, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $291M (up 8.6% year over year) with net income of $47M.
Q3 2026 key financials · XBRL
- Revenue
- $291M
- +8.6% YoY · +2.3% QoQ
- Net income
- $47M
- +16.0% YoY · +4.7% QoQ
- Operating margin
- 21.5%
- Gross margin
- 36.4%
- EPS (diluted)
- $1.46
- +17.7% YoY · +5.8% QoQ
Source: XBRL data from the BALCHEM CORP (BCPC) Q3 2026 10-Q on SEC EDGAR. USD.
BALCHEM CORP Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $290.658M, up 8.6% YoY from $267.558M
- Gross margin 36.4% vs 35.7%; operating margin 21.5% vs 20.4%
- Best segment: Animal Nutrition & Health revenue $62.990M, up 11.7%; worst growth: Specialty Products, up 4.5% to $37.294M
- Operating cash flow $156.544M, up 4.9%; cash $66.264M vs $74.570M at December 31, 2025
- Capital deployment: $71.925M stock repurchases, $40.000M net debt payments, $29.605M capital expenditures and intangible assets
- Outlook risks: geopolitical tensions, energy and raw material costs, freight costs, shipping volatility, tariffs and macroeconomic conditions
Risk Factors
- No material changes to risk factors since the December 31, 2025 Form 10-K
- Key carried-forward risks remain those disclosed in the 2025 Annual Report
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other BALCHEM CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.